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Background-—The joint effect of atherosclerosis and CRP (C-reactive protein) on risk of ischemic stroke (IS) and myocardial
infarction (MI) has been sparsely studied. The aim of this study was to explore whether CRP mediates the risk of events in subjects
with prevalent carotid plaque, examine synergism, and test whether CRP and carotid plaque add to risk prediction beyond
traditional risk factors.
Methods and Results-—CRP and carotid total plaque area (TPA) were measured in 10 109 participants in the Tromsø Study from
1994 to 2008. Incident IS (n=671) and MI (n=1079) were registered until December 31, 2013. We calculated hazard ratios (HRs) of
MI and IS according to categories of CRP (<1, 1–3, and >3 mg/L) and plaque status (no plaque and TPA below and above median)
in Cox proportional hazard models with time-varying covariates. Multivariable-adjusted CRP >3 versus <1 mg/L was associated
with risk of IS (HR, 1.84; 95% confidence interval, 1.49–2.26) and MI (HR, 1.46; 95% confidence interval, 1.23–1.73). TPA above
median versus no plaque was associated with risk for IS (HR, 1.65; 95% confidence interval, 1.36–2.01) and MI (HR, 1.64; 95%
confidence interval, 1.41–1.92). In participants with plaque, adjustment for CRP minimally attenuated the risk estimates. The
highest incidence rates for MI and IS were seen in the group with both CRP >3 mg/L and TPA is above the median. TPA and CRP
combined added to risk prediction beyond traditional risk factors.
Conclusions-—The simultaneous presence of subclinical atherosclerosis and elevated CRP was associated with increased risk of IS
and MI. The combined assessment of subclinical atherosclerosis and inflammatory biomarkers may improve cardiovascular disease
risk stratification. ( J Am Heart Assoc. 2018;7:e008951. DOI: 10.1161/JAHA.118.008951.)
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A pproximately one third of individuals who experience afirst-time cardiovascular event are misclassified as being
at low risk on the basis of traditional risk factors (TRFs).1
Novel biomarkers that can improve cardiovascular disease
(CVD) risk prediction are long awaited. Serum levels of CRP
(C-reactive protein)3 and subclinical atherosclerosis assessed
by carotid ultrasound,2 have both repeatedly been found to
predict future CVD independent of TRFs in large population-
based studies. However, the clinical utility of these factors in
determination of cardiovascular risk is not established.2,4
The development and manifestation of CVD is a complex
process that encompasses several components, including
atherosclerotic plaque development, plaque rupture, and
thromboembolic events. Inflammation is recognized to play
a pivotal role in initiation and progression of atherosclerosis.
CRP is evidently linked to CVD risk, yet the underlying
mechanisms behind these associations are not fully under-
stood. Previous studies do not uniformly support CRP as a
causal agent in plaque formation and progression.5–7 It is
suggested that inflammatory active and rupture-prone
plaques may themselves be a source of CRP.8 In this setting,
CRP would be expected to mediate the relationship between
carotid atherosclerosis and CVD risk because CRP and
atherosclerotic plaques would represent the same underlying
risk factor (ie, unstable plaques). In addition, experimental
studies have indicated that CRP may initiate mechanisms
involved in plaque rupture and thrombus formation.9–11 Thus,
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an interaction between higher serum levels of CRP and
inflammatory active plaques may increase the risk of plaque
rupture and explain the attributable risk of CRP in CVD. In this
scenario, we would expect the simultaneous presence of
elevated CRP and subclinical atherosclerosis to have a
synergistic effect on CVD risk.
Only a few studies have explored whether imaging measures
of atherosclerosis and markers of inflammation interact with
each other in determination of cardiovascular risk, and results
are diverging.12,13 In the Tromsø Study, carotid total plaque
area (TPA) and CRP have been repeatedly measured in a
general, middle-aged, white population. By taking repeated
measurements within individuals into account, we used Cox
proportional hazard models with time-varying covariates, to
investigate the associations between CRP and carotid
atherosclerosis, alone and in combination, with incident
ischemic stroke (IS) and myocardial infarction (MI). We also
examined whether CRP mediated the risk of MI and IS in
subjects with carotid atherosclerosis. Finally, we compared the
predictive performance of models including only TRFs with
models that included TPA, CRP, and TPA+CRP by calculating net
reclassification improvement (NRI) indexes.
Methods
The data, analytical methods, and study materials will not be
made available to other researchers for purposes of repro-
ducing the results or replicating the procedure.
Study Population
Participants were recruited from the fourth, fifth, and sixth
surveys of the Tromsø Study (conducted in 1994–1995,
2001–2002, and 2007–2008, respectively).14 The Tromsø
Study is a population-based prospective study with repeated
health surveys of the inhabitants in the municipality of
Tromsø, Norway. Overall participation rates were high, ranging
from 77% in the fourth survey to 66% in the sixth survey.14
Total birth cohorts and samples from other age groups were
invited to the carotid ultrasound examination,14,15 and 6727,
5454, and 7084 participants completed the fourth, fifth, and
sixth surveys, respectively. Participants who attended ≥1
carotid ultrasound examinations were eligible for the present
study. Participants without valid written consent (n=71),
participants with known prebaseline history of IS (n=121) and
MI (n=527), and participants who did not have information on
CRP, ultrasound measurements, and relevant covariates in at
least 1 of the completed surveys (n=467) were excluded. Our
population thus consisted of 10 109 unique individuals, of
whom 4932 completed 1, 2505 completed 2, and 2672
completed 3 surveys (Figure 1). Informed written consent was
obtained from all participants; the study protocol conforms to
the ethical guidelines of the 1975 Declaration of Helsinki and
was approved by the Regional Committee for Medical and
Health Research Ethics.
Carotid Ultrasound Examination
The baseline and follow-up measurements followed identical
scanning and reading procedures. In the fourth and fifth
survey, ultrasonography was performed with an Acuson Xp10
128 ART ultrasound scanner equipped with a 7.5-MHz linear-
array transducer. In the sixth survey, a GE Vivid 7 scanner
with a linear 12-MHz transducer was used. The far wall and
near wall of the right common carotid artery, the bifurcation
Figure 1. Overview of study inclusion. Dots indicate participa-
tion at the survey, and lines indicate observation periods. A total
of 10 109 unique individuals were included in the study, of whom




• Repeated measures of carotid total plaque area and CRP
(C-reactive protein) were individually associated with
increased risk of ischemic stroke and myocardial infarction.
• CRP only minimally attenuated the risks in subjects with
prevalent carotid plaque, contradictory to what would be
expected if CRP and plaques represent the same underlying
risk factor (ie, unstable plaques).
• The highest incidence rates of ischemic stroke and
myocardial infarction were found in subjects with both total
plaque area above the median and CRP >3 mg/L.
• Inclusion of total plaque area and CRP combined added to
risk prediction models beyond traditional risk factors.
What Are the Clinical Implications?
• The simultaneous presence of subclinical atherosclerosis
and elevated CRP was associated with increased risk of
ischemic stroke and myocardial infarction, indicating that
the combined assessment of subclinical atherosclerosis and
inflammatory biomarkers may improve cardiovascular dis-
ease risk stratification.
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(bulb), and the internal carotid artery (6 locations) were
scanned for the presence of plaques. A plaque was defined as
a localized thickening of the vessel wall of >50% compared
with the adjacent intima-media thickness (IMT). TPA was
calculated as the sum of all plaque areas (mm2). To ensure
equal and standardized examination techniques and mea-
surement procedures, sonographers completed a 2-month
prestudy training protocol. Details about the interobserver
and intraobserver reproducibility and interequipment variabil-
ity have been published previously.16–18
Cardiovascular Risk Factors
Information on TRFs was collected by physical examination,
nonfasting blood samples, and self-administered question-
naires. Blood pressure was recorded with an automatic device
(Dinamap Vital Signs Monitor 1846; Critikon Inc, Tampa, FL)
by trained personnel. Participants rested for 2 minutes in a
sitting position and then 3 readings were taken on the upper
right arm at 1-minute intervals. The average of the 2 last
readings was used in the analyses. Hypertension was defined
as systolic blood pressure >140 mm Hg and/or diastolic
blood pressure >90 mm Hg and/or use of antihypertensive
medication. Body mass index was calculated as weight in
kilograms divided by the square of height in meters (kg/m2).
Nonfasting blood samples were collected from an antecubital
vein. Serum was prepared by centrifugation after 1 hour
respite at room temperature and analyzed at the Department
of Clinical Biochemistry, University Hospital of North Norway.
Serum total cholesterol was analyzed by an enzymatic
colorimetric method using a commercially available kit
(CHOD-PAP; Boehringer-Mannheim, Mannheim, Germany).
Serum high-density lipoprotein cholesterol was measured
after precipitation of lower-density lipoproteins with heparin
and manganese chloride. Determination of glycosylated
hemoglobin in EDTA whole blood was based on an immuno-
turbidimetric assay (UNIMATES; F. Hoffmann-La Roche AG).
The glycosylated hemoglobin percentage value was calculated
from the glycosylated hemoglobin/hemoglobin ratio. Infor-
mation on former MI and stroke, prevalent diabetes mellitus,
current smoking, and use of antihypertensive and lipid-
lowering medication was collected from self-administered
questionnaires. Diabetes mellitus was defined as self-reported
diabetes mellitus, daily use of oral diabetic medication or
insulin, or glycosylated hemoglobin level >6.5%. CRP was
analyzed in thawed aliquots after storage at 70°C (fourth
survey) or 20°C (fifth and sixth surveys) with a particle-
enhanced immunoturbidimetric assay on a Modular P (fourth
and sixth surveys) or Hitachi 917 (fifth survey) autoanalyzer
(Roche Hitachi, Mannheim, Germany), with reagents from
Roche Diagnostics (Mannheim, Germany). Samples from the
fourth survey were analyzed after 12 years of storage, and
samples from the fifth and sixth surveys were analyzed at the
time of the surveys. The lower detection limit of the high-
sensitivity CRP assay was 0.03 mg/L, and measurements of
CRP <0.03 mg/L were set at this value. The analytical
coefficient of variation for CRP levels between 0.1 and
20 mg/L was <4%.
Outcome Assessment
On the basis of data from hospital and out-of-hospital records,
autopsy records, and death certificates, an independent end
point committee validated hospitalized and out-of-hospital
events of incident IS and MI. The national unique 11-digit
identification number was linked to national and local
diagnosis registries, including the National Causes of Death
Registry, the Population Registry of Norway, and the discharge
diagnosis registry (outpatient diagnoses included) at the
University Hospital of North Norway, which is the only
hospital in the municipality of Tromsø. Medical records, death
certificates, autopsy reports, and information from additional
sources, such as records from nursing homes, general
practitioners, and ambulance services, were used for valida-
tion. IS was defined as rapidly developing clinical signs of
focal or global disturbance of cerebral function, with symp-
toms lasting ≥24 hours or leading to death with no apparent
cause other than vascular origin, when computed tomogra-
phy, magnetic resonance imaging, or autopsy had ruled out
intracerebral or subarachnoid hemorrhage.
Cases of incident MI were identified by linkage to the
discharge diagnosis registry at University Hospital of North
Norway with search for International Classification of Diseases,
Ninth Revision (ICD-9) codes 410 to 414 in the period from
1994 to 1998, and thereafter International Classification of
Diseases, Tenth Revision (ICD-10) codes I20 to I25. The hospital
medical records were retrieved for case validation. Modified
World Health Organization MONICA/MORGRAM19 criteria for
MI were used and included clinical symptoms and signs,
findings in ECG, values of cardiac biomarkers, and autopsy
reports, if applicable. Furthermore, linkage to the national
Causes of Death Registry at Statistics Norway allowed inclusion
of fatal cases of MI that occurred out of hospital.
Statistical Analyses
We used the statistical software package SAS, 9.4 (SAS
Institute, Cary, NC) for all data analyses. Differences in
characteristics at time of study entrance between subjects
with and without incident IS and MI were estimated separately
for each outcome by analysis of covariance, adjusted for age
and sex. When treated as continuous variables, CRP was log
transformed and TPA was square root transformed to
approximate normal distribution.
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For each participant, person-years of follow-up were
counted from the first date of enrollment in the fourth, fifth,
or sixth survey to the date of event of interest (separately for
incident IS or MI), emigration from Tromsø, death, or end of
follow-up (December 31, 2013), whichever came first. Follow-
up time and risk estimates were calculated separately for IS
and MI.
In cohorts with long follow-up, temporary fluctuations in
exposure variables (CRP, TPA, and TRFs) over time may result
in underestimation of the true association between exposure
and outcome (regression dilution bias).20 An approach to
minimize the impact of such bias is to perform analyses with
time-varying covariates, and this method was applied in the
present study. Analysis with time-varying covariates uses
individual person data from repeated surveys and takes into
account changes in exposure status during follow-up, by
assigning new observation periods with updated values of
exposure variables at the time of subsequent study atten-
dance. Thus, subjects who completed >1 survey contributed
with 1 observation period per completed survey, and both
exposure (CRP and TPA) and confounder (TRFs) data were
updated at each completed survey. Because of differences in
event censoring, the 10 109 participants contributed with
17 668 observation periods for IS and 17 454 observation
periods for MI. If information on exposure or TRFs was
missing, values from previous assessments were carried
forward, when applicable.
To examine the association between CRP and TPA alone
and in combination with risk of IS and MI, we used Cox
proportional hazard models with time-varying covariates and
age as time scale.21 Sensitivity analyses were performed by
regular Cox models with time-fixed covariates, using values of
exposure and confounder information at time of study
entrance and each individual contributing data only once.
CRP was categorized into low-risk (<1.0 mg/L), interme-
diate-risk (1.0–3.0 mg/L), and high-risk (>3.0 mg/L) groups
in accordance with American Heart Association and the
Centers for Disease Control and Prevention guidelines for
cardiovascular risk.22 We calculated incidence rates and
hazard ratios (HRs) with 95% confidence intervals (CIs) for IS
and MI using the low-risk group as reference, first in age-
adjusted models and second in models adjusted for TRFs. The
TRFs included were current smoking status, total cholesterol,
high-density lipoprotein cholesterol, systolic blood pressure,
diabetes mellitus, body mass index, and use of antihyperten-
sive and lipid-lowering medication, which were reliably
assessed in the Tromsø Study, and have previously shown
associations both with exposure (TPA and CRP)2,3,23 and
outcome (IS and MI).
We defined 3 categories of plaque; categories of TPA were
defined separately for men and women at each survey and
divided below and above the median, whereas subjects with
no plaque constituted the reference category. We estimated
HRs with 95% CIs for IS and MI across plaque categories. To
address the impact of CRP on the relationship between plaque
and the outcomes, we performed age- and sex-adjusted
analyses (model 1) and analyses with additional adjustment
for CRP (model 1+CRP) and calculated the percentage change
in HR when CRP (log transformed) was added to the model. In
the final model, we included the previously listed TRFs in
addition to CRP (model 2).
Multiplicative interactions between CRP and TPA were
assessed. To investigate synergistic effects of atherosclerosis
and CRP on the risk of IS and MI, we calculated incidence
rates and HRs for the other 8 constellations of atherosclerosis
and CRP, and these were compared with the no plaque group
with CRP <1 mg/L. Additive interaction and synergism was
evaluated using the Rothman synergy index24 to determine
whether the joint effects of CRP and atherosclerosis on the
risk of IS and MI exceeded the sum of effects from each factor
alone in age- and sex-adjusted models. The synergy index,
with corresponding 95% CIs, was calculated according to
Andersson et al25 using an Excel sheet (epinet.se/res/xls/
epinetcalculation.xls) comparing the following 4 constella-
tions: no atherosclerosis and CRP <1 mg/L (reference), no
atherosclerosis and CRP >3 mg/L, TPA>median and CRP
<1 mg/L, TPA>median and CRP >3 mg/L. A synergy index
>1.0 suggests that the effect of the joint exposures of 2 risk
markers is greater than the sum of the separate effects.
The added value by TPA and CRP in risk prediction was
evaluated by comparing the discrimination power of a model
based on the Framingham risk factors (FRFs) with models that
additionally included TPA alone, CRP alone, and TPA+CRP
together. Original Framingham risk score coefficients were
not used because of possible issues of the applicability to
different populations.26 For each outcome, a baseline Cox
proportional hazard model with time-fixed covariates was
created, using values of FRFs (sex, age, systolic blood
pressure, high-density lipoprotein cholesterol, total choles-
terol, smoking, and antihypertensive medication) at time of
study entrance. The exposure variables (TPA and CRP), at time
of study entrance, were then subsequently included alone and
in combination to estimate individual 10 years’ risk for MI and
IS. CRP and TPA were included both as continuous and
categorical variables. We calculated Harrell’s C-index,27 which
is an extension of the receiver operating characteristic curve
for survival data. Finally, we computed the relative integrative
discrimination improvement and NRI. We considered cate-
gories of predicted risk (0%–5%, 5%–10%, 10%–20%, and
>20%) and applied SAS macros available in the article by Cook
and Ridker.28,29 Bootstrapping methods (n=500 replications),
available at Cook’s web page,30 were used to compute 95%
CIs for Harrell’s C-index, integrative discrimination improve-
ment, and NRI and test for difference between models by
DOI: 10.1161/JAHA.118.008951 Journal of the American Heart Association 4
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evaluation of P values estimated by the bootstrapping
methods. We also considered improvements in discrimination
indexes separately for the groups classified to be at
intermediate risk (5%–20%) by the FRF-based models.
For all Cox proportional hazard regression models, the
proportional hazard assumption was verified by visual
inspection of log-log survival plots.
Results
Mean age at inclusion was 59.48.9 years (range, 25–84
years). Median observation time was 11.0 years (range, 0.01–
19.3 years). The study population consisted of 5704 women
and 4405 men with a total of 114 716 person-years for IS
and 112 817 person-years for MI. Table 1 shows crude
characteristics of the study population at each survey; sex-
stratified characteristics are presented in Table S1.
Table 2 shows age- and sex-adjusted population charac-
teristics at time of study entrance, according to incident IS
and MI. In general, levels of TRFs, CRP, plaque prevalence,
and TPA were higher in subjects who experienced incident IS
or MI during the study period. High-density lipoprotein
cholesterol was lower in subjects who experienced IS or MI.
TPA showed a significant weak correlation to CRP, with
Spearman correlation coefficient of 0.13 (P<0.001). CRP level
was >3 mg/L in 22.4% of all observations. Risk estimates for
IS and MI across CRP risk categories are shown in Table 3.
CRP level >3 mg/L compared with <1 mg/L was associated
with increased risk of IS (HR, 1.84; 95% CI, 1.49–2.26) and MI
(HR, 1.46; 95% CI, 1.23–1.73) in multivariable-adjusted
models. Sex-stratified analyses are displayed in Tables S2
and S3; however, there was no significant interaction with sex
for either outcome.
HRs for IS and MI across predefined plaque categories are
shown in Table 4. In age- and sex-adjusted models, both TPA
values below and above the median were associated with
higher risk of IS and MI compared with no plaque. Adding CRP
to these models led to minimal attenuation of the risk
estimates, with absolute attenuation varying from 1.7% to
8.6%. Additional adjustment for TRFs (model 2) led to further
attenuation of the risk estimates, but plaque still remained a
significant predictor of IS, with HRs (95% CIs) of 1.33 (1.08–
1.65) and 1.65 (1.36– 2.01), referring to TPA below and above
median, respectively. For MI, the corresponding HRs (95% CIs)
were 1.31 (1.11–1.55) and 1.64 (1.41–1.92). Sex-specific
estimates are presented in Tables S4 and S5. For MI but not for
IS, there was a significant interaction between plaque category
and sex (P=0.02). A stronger association between TPA and risk
of MI in women than in men was suggested (Table S5).
Age- and sex-adjusted HRs of IS and MI across the
different constellations of CRP and plaque categories are
displayed in Figure 2. Incidence rates and HRs for IS and MI
across these categories are listed in Table S6. Subjects with
the joint presence of CRP >3 mg/L and TPA above median








No. of observations 6116 5116 6726
Men, % (n) 47.8 (2922) 42.4 (2168) 42.0 (2824)
Age, mean (SD), y 59.8 (10.3) 65.5 (9.6) 63.5 (9.2)
BMI, mean (SD), kg/m2 26.0 (3.9) 26.8 (4.2) 27.0 (4.2)
Carotid plaque, % (n) 47.4 (2896) 58.3 (2983) 44.9 (3020)
TPA, median (IQR), mm2* 15.0 (8.7–26.2) 20.3 (11.3–35.8) 19.1 (11.0–31.5)
CRP, median (IQR), mg/L 1.21 (0.61–2.54) 1.55 (0.83–3.13) 1.37 (0.77–2.55)
Systolic blood pressure, mean (SD), mm Hg 145 (22) 143 (22) 141 (23)
Diastolic blood pressure, mean (SD), mm Hg 83 (13) 82 (13) 78 (11)
Hypertension, % (n) 56.3 (3446) 60.6 (3100) 58.4 (3931)
Antihypertensive medication, % (n) 11.6 (711) 23.4 (1197) 27.3 (1836)
HDL cholesterol, mean (SD), mmol/L 1.6 (0.4) 1.5 (0.4) 1.6 (0.4)
Total cholesterol, mean (SD), mmol/L 6.7 (1.3) 6.3 (1.2) 5.8 (1.1)
Lipid-lowering medication, % (n) 1.7 (101) 12.6 (643) 16.6 (1115)
Diabetes mellitus, % (n) 3.7 (227) 8.3 (426) 7.6 (514)
Smoking, % (n) 31.1 (2025) 25.0 (1276) 17.8 (1200)
BMI indicates body mass index; CRP, C-reactive protein; HDL, high-density lipoprotein; IQR, interquartile range; TPA, total plaque area.
*In subjects with prevalent carotid plaque. In total, 10 109 participants were included in the study; of these, 4932 completed 1, 2505 completed 2, and 2672 completed 3 surveys.
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had the highest incidence rates for both outcomes. For IS,
there was a significant excess additive risk when both TPA
was above median and CRP was >3 mg/L, with a synergy
index of 1.72 (95% CI, 1.06–2.81). The attributable proportion
because of interaction was 31.6%. However, there was no
indication of synergistic effects between TPA and CRP on risk
of MI (Table S7).
There were no significant multiplicative interactions
between CRP and TPA category for either outcome. However,
there was a nonsignificant trend of increasing magnitude of
CRP risk estimates for IS by increasing TPA (Table S8).
In sensitivity analyses, considering values of exposure (CRP
and TPA) and TRFs at time of study entrance in regular time-
fixed Cox models (Tables S9 through S13), the risk estimates
were slightly weaker for both outcomes compared with time-
varying analyses, but significance remained unchanged.
When TPA was added as a continuous variable to FRF-
based models, the C-index improved for prediction of both IS
(P=0.040) and MI (P=0.013) (Table S14 and S15). When
considering NRI across risk categories (<5%, 5%–10%, 10%–
20%, and >20%), the overall NRI for IS was 2.8% (P=0.226),
and net improvement was 2.3% for cases and 0.6% for
noncases. Overall NRI for MI when adding TPA to FRFs was
3.8% (P=0.030), with a net improvement of 2.5% for MI cases
and 1.2% for noncases. The estimate of relative integrative
discrimination improvement was 0.16 (P=0.0023) for IS and
0.07 (P<0.0001) for MI. When considering only the interme-
diate-risk group, overall NRI was 14.4% (P<0.001) for IS and
10.5% (P=0.035) for MI (Table S16 and S17).
There were no significant differences in C-index, integrative
discrimination improvement, or overall categorical NRI for
either outcome after addition of CRP as a continuous variable
to FRFs in the whole population. Categorical NRI was 3.6% for
IS and 3.7% for MI when CRP was included as a categorical
variable. In the intermediate-risk group, NRI was 12.6% for IS
and 8.2% for MI after addition of CRP. For IS, the highest
categorical NRIs were seen when including both variables
(CRP+TPA) as continuous variables, 6.6% (P=0.007) for the
population and 21.6% (P<0.001) for the intermediate-risk
group. For MI, the highest NRIs of 5.0% (P=0.01) for the
population and 12.0% (P=0.02) for the intermediate-risk group
were seen when both variables were included as categorical
variables.
Discussion
Serum CRP levels and carotid atherosclerosis were individu-
ally associated with increased risk of IS and MI, independent
Table 2. Age- and Sex-Adjusted Baseline Characteristics of the Study Population, According to First-Ever IS and MI: The Tromsø
Study
Characteristics Subjects Without IS
Subjects With
Incident IS P Value Subjects Without MI
Subjects With
Incident MI P Value
No. of participants 9438 671 . . . 9030 1079 . . .
Men, % (n)* 43.0 (4060) 51.4 (345) <0.0001 41.8 (3773) 58.7 (633) <0.0001
Age, mean (95% CI), y* 59.0 (58.8–59.2) 64.9 (64.3–65.6) <0.0001 58.9 (58.7–59.1) 63.7 (63.2–64.2) <0.0001
BMI, mean (95% CI), kg/m2 26.3 (26.2–26.4) 26.5 (26.2–26.8) 0.438 26.3 (26.2–26.4) 26.6 (26.4–26.9) 0.034
Carotid plaque, % (n) 42.7 (4030) 55.2 (370) <0.0001 42.0 (3793) 55.9 (603) <0.0001
TPA, mean (95% CI), mm2† 4.2 (4.2–4.3) 4.4 (4.3–4.6) 0.0028 4.2 (4.1–4.2) 4.4 (4.3–4.5) 0.0009
CRP, mean (95% CI), mg/L‡ 1.34 (1.31–1.37) 1.59 (1.46–1.72) <0.0001 1.34 (1.31–1.37) 1.53 (1.44–1.63) <0.0001
Systolic blood pressure, mean (95% CI), mm Hg 141 (140–141) 149 (148–151) <0.0001 140 (140–141) 148 (147–150) <0.0001
Diastolic blood pressure, mean (95% CI), mm Hg 81.3 (81.0–81.5) 85.4 (84.5–86.3) <0.0001 81.1 (80.9–81.3) 85.3 (84.5–86.0) <0.0001
Hypertension, % (n) 51.0 (4817) 63.8 (428) <0.0001 50.4 (4559) 63.7 (687) <0.0001
Antihypertensive medication, % (n) 14.7 (1387) 18.2 (122) 0.062 14.5 (1309) 17.9 (193) 0.019
Total cholesterol, mean (95% CI), mmol/L 6.39 (6.36–6.41) 6.62 (6.53–6.72) <0.0001 6.35 (6.33–6.38) 6.83 (6.76–6.91) <0.0001
HDL cholesterol, mean (95% CI), mmol/L 1.56 (1.55–1.57) 1.52 (1.49–1.55) 0.0092 1.57 (1.56–1.58) 1.47 (1.44–1.49) <0.0001
Lipid-lowering medication, % (n) 5.1 (481) 3.3 (22) 0.007 5.2 (470) 3.2 (35) 0.006
Diabetes mellitus, % (n) 4.3 (406) 7.4 (50) 0.002 4.2 (379) 6.6 (71) 0.003
Smoking, % (n) 28.1 (2652) 33.6 (225) 0.002 27.3 (2466) 40.4 (436) <0.0001
Each subject contributed with observations at time of study inclusion. P value for equality between subjects with incident events and subjects without events during follow-up. BMI
indicates body mass index; CI, confidence interval; CRP, C-reactive protein; HDL, high-density lipoprotein; IS, ischemic stroke; MI, myocardial infarction; TPA, total plaque area.
*Unadjusted.
†Square root–transformed TPA in subjects with prevalent carotid plaque.
‡Geometric means.
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of TRFs. Risk estimates for subjects with atherosclerosis were
only slightly attenuated after adjustment for CRP. For both
outcomes, the joint presence of TPA above median and CRP
>3 mg/L was associated with the highest incidence rates.
However, a synergistic effect was evident for IS only. TPA
alone and the combination of CRP and TPA achieved small,
but significant, improvements in risk prediction beyond FRFs,
with most prominent effects in the group classified to be at
intermediate risk by FRFs.
TRFs have well-known limitations for accurate assessment
of individual cardiovascular risk.1,31 It is crucial to identify
biomarkers that may improve the identification of subjects at
risk and guide preventive treatment. Carotid ultrasound is
noninvasive and easily accessible, and it can provide direct
evidence for the presence and extent of subclinical atheroscle-
rosis with the potential for a more accurate personalized risk
assessment and treatment approach.31 Ultrasound assessed
measures of subclinical atherosclerosis in carotid arteries;
Table 4. Crude IRs and HRs With 95% CIs of First-Ever IS and MI From Time-Varying Cox Models Across Categories of TPA Before
and After Adjustment for CRP: The Tromsø Study (1994–2013)












HR After Inclusion of




No plaque 8945 177 3.1 (2.6–3.5) Reference Reference . . . . . . Reference
TPA below median 4362 177 6.2 (5.3–7.2) 1.37 (1.11–1.69) 1.36 (1.10–1.68) 0.01 1.7 1.33 (1.08–1.65)
TPA above median 4361 317 11.2 (10.1–12.6) 1.93 (1.31–1.77) 1.85 (1.53–2.24) 0.08 8.6 1.65 (1.36–2.01)
MI
No plaque 8881 300 5.2 (4.7–5.9) Reference Reference . . . . . . Reference
TPA below median 4285 291 10.4 (9.3–11.7) 1.47 (1.25–1.73) 1.46 (1.24–1.72) 0.01 2.1 1.31 (1.11–1.55)
TPA above median 4288 488 17.7 (16.2–19.4) 2.14 (1.84–2.49) 2.07 (1.78–2.41) 0.07 6.1 1.64 (1.41–1.92)
CI indicates confidence interval; CRP, C-reactive protein; HR, hazard ratio; IR, incidence rate; IS, ischemic stroke; MI, myocardial infarction; TPA, total plaque area.
*Observations.
†Crude IRs per 1000 person-years.
‡Age as time scale, adjusted for sex.
§Change in HR from model 1 to model 1+CRP. CRP was log transformed.
||Age as time scale, adjusted for sex, total cholesterol, high-density lipoprotein cholesterol, diabetes mellitus, systolic blood pressure, smoking, body mass index, lipid-lowering medication,
antihypertensive medication, and CRP (log transformed).
Table 3. Crude IRs and HRs With 95% CIs of First-Ever IS and MI From Time-Varying Cox Models Across Risk Categories of CRP:
The Tromsø Study (1994–2013)
CRP, mg/L n* Events IR (95% CI)†
HR (95% CI)
Model 1‡ Model 2§
IS
<1 6690 161 3.7 (3.2–4.3) Reference Reference
1–3 7024 261 5.7 (5.0–6.4) 1.27 (1.04–1.55) 1.15 (0.94–1.41)
>3 3954 249 10.0 (8.8–11.3) 2.18 (1.79–2.67) 1.84 (1.49–2.26)
MI
<1 6605 262 6.1 (5.4–6.9) Reference Reference
1–3 6938 467 10.4 (9.5–11.3) 1.45 (1.25–1.69) 1.25 (1.07–1.46)
>3 3911 350 14.2 (12.8–15.7) 1.95 (1.66–2.29) 1.46 (1.23–1.73)
CI indicates confidence interval; CRP, C-reactive protein; HR, hazard ratio; IR, incidence rate; IS, ischemic stroke; MI, myocardial infarction.
*Observations.
†Crude IRs per 1000 person-years.
‡Age as time scale, adjusted for sex.
§Age as time scale, adjusted for sex, total cholesterol, high-density lipoprotein cholesterol, diabetes mellitus, systolic blood pressure, smoking, body mass index, lipid-lowering medication,
and antihypertensive medication.
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plaque presence,32 plaque echogenicity,33,34 plaque
area,35,36 and IMT37 are reliable predictors of CVD, even
after adjustment for TRFs. The European Guidelines on CVD
prevention suggest that imaging methods for atherosclerotic
burden are relevant, especially in individuals at intermediate
risk based on TRFs, to improve cardiovascular risk stratifi-
cation and preventive strategy.38,39 Methodological issues
about measurement of carotid IMT on the individual level
have been raised, and in the most recent guidelines,40,41 IMT
screening is not recommended. On the other hand, carotid
artery plaque assessment, including thickness and TPA, has
been proposed as risk modifiers in CVD risk prediction, but
formal reclassification analyses have not yet been fully
evaluated.40 NRI added by plaque measures in CVD risk
prediction has previously been reported by the ARIC
(Atherosclerosis Risk in Communities) Study and Three City
Study, with overall categorical NRI ranging from 7.7% to
13.1%.42,43 Differences in plaque assessment, outcome of
interest, definition of plaque categories, and incidence rates
exist. This may explain discrepancies in results and compli-
cates comparison between studies. For plaque area, the risk
estimates in our study were stronger in women than in men,
suggesting that assessment of carotid plaque may be a more
important tool in risk classification of women than in men. It
is suggested that <10% of the population who test positive
for atherosclerosis will experience a near-term event.1
Identification of reliable imaging and serological markers of
disease activity is therefore essential to improve the
selection of vulnerable patients and cost-effectiveness of
screening with carotid ultrasound in the primary prevention
setting.
Inflammation plays a pivotal role in the initiation, progres-
sion, and complications of atherosclerosis. Hence, the
prognostic value of circulating inflammatory markers in CVD
prediction has been assessed in numerous epidemiologic
studies. CRP is the marker of inflammation that has been
most extensively studied in relation to CVD.3 Most epidemi-
ological studies have reported a moderate dose-responsive
relationship between CRP and clinically relevant CVD out-
comes after adjusting for TRFs. Increase in relative risk
estimates for CVD ranges from 1.45- to 2-fold when
comparing the highest with the lowest CRP tertile.44 This is
comparable to the effect of TRFs, such as blood cholesterol
and blood pressure.44 A meta-analysis comprising individual
participant records from 54 long-term prospective studies3
reported 1.37 (95% CI, 1.27–1.48) relative risk increase for
coronary heart disease and 1.27 (95% CI, 1.15– 1.40) relative
risk increase for IS per SD increase in log-transformed CRP
after adjustment for TRFs. These results concur with our risk
estimate for IS, but the risk estimate for MI was weaker in our
study (1.13; 95% CI, 1.06–1.20) (Table S8). Our results are
concordant with the meta-analysis by Shah et al, which
Figure 2. Age- and sex-adjusted hazard ratios of ischemic stroke (A) and myocardial infarction (B) across different constellations of C-reactive
protein (CRP) and total plaque area (TPA). Bottom panels show contributions from different exposure categories on risk for ischemic stroke (C)
and myocardial infarction (D). U indicates common reference category for each outcome.
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concludes that CRP does not perform better than the FRFs for
discrimination in coronary heart disease.4
Despite the evident association between CRP and CVD, the
pathogenic role of CRP in CVD remains unclear. Large
population-based cohort studies failed to demonstrate an
independent association between CRP and early stages and
progression of atherosclerosis measured by carotid IMT.45
These findings are supported by recent results of genomic,6,46
epidemiological,7,45 and experimental studies on CRP, which
have not proved a causal role of CRP in the formation and
progression of atherosclerosis.5,47 In addition, some contro-
versy about the prognostic value of CRP in CVD prediction still
remains,48 and few studies have explored whether CRP’s
ability to predict CVD is dependent on the presence of
atherosclerosis.12,13 Cao and colleagues concluded that CRP
>3 mg/L was a particularly useful predictor in the presence
of subclinical atherosclerosis, with a 72% increase in risk for
CVD and a 52% increase in total mortality.12 However, CRP
did not add predictive power in the absence of carotid
atherosclerosis, and an additive interaction for composite
CVD and all-cause mortality was suggested.12 Contradictory,
CRP was associated with CVD events with a similar magnitude
in the presence and absence of atherosclerosis in the ARIC
Study population, but additive interaction of these measures
was not assessed.13
In our study, adjustment for CRP led to only minimal
attenuation of the risk estimates in participants with plaque.
This questions the theory that inflammatory active rupture-
prone plaques secrete CRP.8 In this scenario, CRP and carotid
plaques should represent the same underlying risk factor (ie,
unstable plaques), and a more substantial attenuation of the
risk estimates would be expected on adjustment for CRP. In
line with these findings, it is not firmly established that CRP
correlates to vulnerable plaque characteristics.49–51
Our study suggests synergistic effects of CRP and plaque
in determination of IS risk. Elevated CRP may be related to
mechanisms involved in plaque rupture in acute CVD
syndromes, such as production of proteolytic metallopro-
teinases (matrix metalloproteinases 2 and 9).9 In addition,
CRP is closely correlated to obesity, diabetes mellitus,
hypercholesterolemia, and cigarette smoking.1,3,8 These are
all conditions that lead to a prothrombotic state.1 CRP has
been shown to induce tissue factor expression by vascular
endothelial cells and smooth muscle cells and increase
plasminogen activator inhibitor-1 activity with concomitant
reduction in tissue type plasminogen activator activity,
resulting in overall impaired fibrinolysis.10 The role of the
coagulation system in the outcome of plaque complications is
essential. An interaction between CRP and inflammatory
active plaques may thus increase risk of plaque rupture and
thrombus formation.11 Because mendelian randomization
studies and animal studies have not supported a causal role
of CRP in CVD, it may be more likely that CRP as a nonspecific
marker of inflammation increases secondarily to upstream
processes, which are more directly linked to the pathogenesis
of CVD.5 However, one limitation of mendelian randomization
studies is that the power to detect meaningful gene-
environment interaction is low.52 To our knowledge, it has
not been tested whether gene polymorphisms associated with
increased serum levels of CRP may have different effects in
determining CVD events in the presence and absence of
atherosclerosis. Although carotid atherosclerosis may be
considered a direct part taker in IS, it is more indirectly
correlated with coronary disease, and this may partly explain
the lack of synergistic effects on risk of MI in the present
study. Assessment of atherosclerosis in coronary arteries may
provide evidence of synergistic effects in regard to MI.
Unfortunately, coronary computed tomographic scans were
not performed in the Tromsø Study.
The strengths of this study are the population-based
design, the large sample of repeated individual data,
standardized diagnostic criteria, rigorous validation of cases,
and high attendance rate. The unavailability for follow-up is
negligible because of use of the unique personal identity
number to search official health registries. One single
hospital provides all hospital care in the region, which
facilitates the completeness of our outcome registries.
However, case identification was retrospective, and some
nonhospitalized nonfatal cases may not have been identified.
Although we used a standardized protocol for TPA assess-
ment, these measurements are prone to measurement error.
The use of different ultrasonography equipment in the fourth
and the sixth survey and nonstandardized uptake angles are
likely to have increased the measurement error between
surveys. We aimed to diminish the effect of measurement
errors by defining TPA medians separately at each survey. A
limitation of our study is that our ultrasound protocol
included examination of only the right carotid artery, and
plaques in the left artery were not acknowledged. Our
classification of atherosclerosis was designated to study the
interaction of carotid atherosclerosis and CRP, and this limits
the comparability with other studies. If the stability of CRP is
affected by freezing, thawing, or storage, bias may be
introduced by the use of frozen blood samples. In the present
study, CRP was analyzed in thawed serum aliquots after
12 years (fourth survey) or consecutively during the course of
the study (fifth and sixth surveys). CRP stability in frozen
samples was previously reported to be acceptable, with high
correlations between CRP values obtained before and after
storage.53
The use of updated exposure variables on subsequent
surveys may have diminished regression dilution effects and
survival bias related to subsequent study attendance.
Response bias may have distorted the validity of covariates,
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such as self-reported smoking, diabetes mellitus, and med-
ication use. Selection bias may have affected the estimates,
because attendance rates were lower in elderly people, who
are at higher risk of CVD. We did not perform competing risk
analyses, meaning that the occurrence of the event of interest
(IS and MI) could have been impeded by competing events.
Our study population consisted of middle-aged whites and our
results may not be generalizable to populations of other racial
and age compositions.
In conclusion, we found that repeated measurements of
CRP and plaque burden, assessed by TPA in carotid arteries,
individually were predictors of IS and MI, independent of TRFs.
The joint presence of elevated CRP and carotid atheroscle-
rosis was associated with the highest incidence rates of IS
and MI. Our results extend previous findings and indicate that
these measures may have synergistic effects in the determi-
nation of CVD risk. CRP has been linked to mechanisms
involved in plaque rupture and thrombus formation, which
may explain synergism. Future research should focus on
whether addition of emerging biomarkers, particularly indica-
tive of unstable plaque features, improves individualized risk
assessment and should evaluate cost-effectiveness of mea-
suring these biomarkers in primary and secondary CVD
prevention.
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Table S1. Distribution of risk factors in the different surveys stratified by sex. The Tromsø Study. 
 
                                      Women 
                                            (n = 5704) 
  
                                 Men 














Number of observations 3194 2948 3902  2922 2168 2824 
Age (years), mean (SD) 60.3 (10.4) 65.4 (9.8) 63.6 (9.3)  59.1 (10.2) 65.5 (9.4) 63.5 (9.1) 
BMI (kg/m2), mean (SD) 25.9 (4.5) 26.8 (4.6) 26.8 (4.6)  26.0 (3.3) 26.7 (3.4) 27.3 (3.7) 
Carotid plaque, %  44.0 53.0 41.2  51.0 65.5 50.0 
























Systolic blood pressure (mmHg), mean (SD) 145 (24) 145 (23) 140 (25)  145 (20) 144 (20) 142 (20) 
Diastolic blood pressure (mmHg), mean (SD) 82 (13) 81 (13) 76 (10)  85 (12) 83 (12) 82 (10) 
Hypertension (SD), %  54.9 59.9 56.9  57.9 61.6 60.6 
Antihypertensive medication, %  12.2 23.5 28.9  11.0 23.3 26.2 
Total cholesterol (mmol/L), mean (SD) 6.9 (1.3) 6.5 (1.2) 5.9 (1.1)  6.5 (1.2) 6.1 (1.1) 5.6 (1.1) 
HDL cholesterol (mmol/L), mean (SD) 1.7 (0.4) 1.6 (0.4) 1.7 (0.4)  1.4 (0.4) 1.4 (0.4) 1.4 (0.4) 
Lipid-lowering medication, %  1.8 10.9 16.0  1.5 14.9 17.4 
Diabetes mellitus, %  3.8 7.3 7.2  3.6 9.8 8.2 
Smoking, %  31.1 24.7 18.7  35.4 25.3 16.6 
BMI, body mass index; TPA, total plaque area; CRP, C-reactive protein; HDL, high-density lipoprotein; n, number of participants; IQR, interquartile range; SD, standard deviation. *If 








Table S2. Sex stratified incidence rates (IRs) and hazard ratios (HRs) with 95% confidence intervals (CIs) of first-ever ischemic stroke from time-varying Cox models across risk 
categories of C-reactive protein (CRP). The Tromsø Study. 
CRP n * Events 
IR†  
(95% CI) 
Model 1‡  
HR (95% CI) 
Model 2§  
HR (95% CI) 
Men 
< 1 mg /L 2820 83 4.5 (3.7, 5.6) Reference Reference 
1–3 mg/L 3209 130 6.3 (5.3, 7.5) 1.19 (0.90, 1.57) 1.06 (0.80, 1.41) 
> 3 mg/L 1743 132 12.5 (10.5, 14.8) 2.24 (1.70, 2.95) 1.84 (1.39, 2.45) 
Women 
< 1 mg /L 3870 78 3.1 (2.5, 3.8) Reference Reference 
1–3 mg/L 3815 131 5.2 (4.3, 6.1) 1.36 (1.02, 1.80) 1.23 (0.92, 1.64) 
> 3 mg/L 2211 117 8.1 (6.8, 9.7) 2.14 (1.61, 2.86) 1.79 (1.32, 2.43) 
*Observations. †Crude IRs per 1000 person-years. ‡ Age as time-scale. §Age as time-scale, adjusted for total cholesterol, high-density lipoprotein cholesterol, diabetes mellitus, 









Table S3. Sex stratified incidence rates (IRs) and hazard ratios (HRs) with 95% confidence intervals (CIs) of first-ever myocardial infarction from time-varying Cox models across 
risk categories of C-reactive protein (CRP). The Tromsø Study. 
CRP n * Events 
IR† 
(95% CI) 
Model 1‡  
HR (95% CI) 
Model 2§  
HR (95% CI) 
Men 
< 1 mg /L 2758 149 8.4 (7.1, 9.8) Reference Reference 
1–3 mg/L 3156 282 14.1 (12.5, 15.8) 1.52 (1.25, 1.86) 1.31(1.07, 1.61) 
> 3 mg/L 1708 202 19.6 (17.1, 22.5) 2.03 (1.64, 2.51) 1.56 (1.25, 1.94) 
Women 
< 1 mg /L 3847 113 4.5 (3.7, 5.4) Reference Reference 
1–3 mg/L 3782 185 7.4 (6.4, 8.5) 1.35 (1.07, 1.70) 1.14 (0.90, 1.46) 
> 3 mg/L 2203 148 10.3 (8.7, 12.1) 1.83 (1.43, 2.33) 1.36 (1.04, 1.76) 
*Observations. †Crude IRs per 1000 person-years. ‡ Age as time-scale. § Age as time-scale, adjusted for total cholesterol, high-density lipoprotein cholesterol, diabetes mellitus, 
systolic blood pressure, smoking, body mass index, lipid-lowering medication and antihypertensive medication.  D
ow
nloaded from




Table S4. Sex stratified incidence rates (IRs) and hazard ratios (HRs) with 95% confidence intervals (CIs) of first-ever ischemic stroke from time-varying Cox models across 
categories of total plaque area (TPA) before and after adjustment for C-reactive protein (CRP). The Tromsø Study. 
 
TPA n *  Events IR† (95% CI) 
Model 1‡  
HR (95% CI) 
Model 1‡ + CRP  
HR (95% CI) 
Absolute attenuation of HR 
after inclusion of CRP in the 
model§ 
Percentage attenuation of HR 
after inclusion of CRP in the 
model 
Model 2|| HR  
(95% CI) 
Men 
No plaque 3543 89 3.9 (3.2, 4.8) Reference Reference – – Reference 
TPA<median 2115 93 6.9 (5.6, 8.4) 1.27 (0.94, 1.70) 1.25 (0.93, 1.68) 0.02  7.4 1.16 (0.87, 1.56) 
TPA>median 2114 163 12.4 (10.7, 14.5) 1.81 (1.38, 2.37) 1.72 (1.31, 2.24) 0.09 11.1 1.45 (1.11, 1.91) 
Women 
No plaque 5402 88 2.5 (2.0, 3.1) Reference Reference – – Reference 
TPA<median 2247 84 5.6 (4.5, 6.9) 1.46 (1.08, 1.98) 1.46 (1.07, 1.97) 0.00  – 1.41 (1.04, 1.91) 
TPA>median 2247 154 10.2 (8.7, 11.9) 2.03 (1.54, 2.67) 1.96 (1.49, 2.58) 0.07 6.8 1.72 (1.30, 2.28) 
*Observations. †Crude IRs per 1000 person-years. ‡ Age as time-scale. § Change in HR from Model 1 to Model 1 + CRP. CRP was log-transformed. || Age as time-scale, adjusted for 
total cholesterol, high-density lipoprotein cholesterol, diabetes mellitus, systolic blood pressure, smoking, body mass index, lipid -lowering medication, antihypertensive medication 





















Table S5. Sex stratified incidence rates (IRs) and hazard ratios (HRs) with 95% confidence intervals (CIs) of first-ever myocardial infarction from time-varying Cox models across 
categories of total plaque area (TPA) before and after adjustment for C-reactive protein (CRP). The Tromsø Study. 
 
TPA n *  Events IR† (95% CI) 
Model 1‡ 
 HR (95% CI) 
Model 1‡ + CRP  
HR (95% CI) 
Absolute attenuation of 
HR after inclusion of CRP 
in the model§ 
Percentage attenuation of HR 
after inclusion of CRP in the 
model 
Model 2|| HR  
(95% CI) 
Men 
No plaque 3493 178 8.0 (6.9, 9.2) Reference Reference – – Reference 
TPA<median 2043 173 13.2 (11.4, 15.3) 1.36 (1.10, 1.68) 1.35 (1.09, 1.67) 0.01  2.7 1.22 (0.98, 1.51) 
TPA>median 2065 282 22.2 (19.7, 24.9) 1.99 (1.63, 2.43) 1.91 (1.56, 2.32) 0.08 8.1 1.57 (1.29, 1.93) 
Women 
No plaque 5388 122 3.5 (2.9, 4.2) Reference Reference – – Reference 
TPA<median 2221 118 7.9 (6.6, 9.2) 1.61 (1.25, 2.08) 1.60 (1.24, 2.07) 0.01  1.6 1.46 (1.13, 1.89) 
TPA>median 2223 206 13.9 (12.1, 15.9) 2.34 (1.85, 2.95) 2.28 (1.81, 2.88) 0.06  4.5 1.75 (1.38, 2.23) 
*Observations. †Crude IRs per 1000 person-years. ‡ Age as time-scale. § Change in HR from Model 1 to Model 1 + CRP. CRP was log-transformed. || Age as time-scale, adjusted for 
total cholesterol, high-density lipoprotein cholesterol, diabetes mellitus, systolic blood pressure, smoking, body mass index, lipid-lowering medication, antihypertensive medication 










Table S6. Incidence rates (IRs) and hazard ratios (HRs) with 95% confidence intervals (CIs) of first-ever ischemic stroke (IS) and myocardial infarction (MI) from 
time-varying Cox models across constellations of C-reactive protein (CRP) and categories of total plaque area (TPA). The Tromsø Study. 
 
 Ischemic stroke                                Myocardial infraction 












Both sexes§      
No plaque & CRP <1 mg/L 3784 51 2.1 (1.6, 2.7) Ref.  3762 72 2.9 (2.3, 3.7) Ref. 
No plaque & CRP 1-3mg/L 3436 71 3.2 (2.5, 4.0) 1.25 (0.87, 1.79)  3409 140 6.4 (5.4, 7.5) 1.86 (1.40, 2.48) 
No plaque & CRP >3 mg/L 1725 55 5.0 (3.8, 6.5) 1.93 (1.32, 2.82)  1710 88 8.0 (6.5, 9.9) 2.36 (1.73, 3.22) 
TPA<median & CRP <1 mg/L 1608 41 3.9 (2.9, 5.3) 1.22 (0.81, 1.84)  1581 82 8.0 (6.5, 10.0) 1.96 (1.43, 2.69) 
TPA<median & CRP 1-3 mg/L 1756 79 6.8 (5.4, 8.4) 1.86 (1.30, 2.65)  1724 108 9.4 (7.8, 11.4) 2.10 (1.55, 2.83) 
TPA<median & CRP >3 mg/L 997 57 9.0 (6.9, 11.6) 2.50 (1.70, 3.65)  980 101 16.3 (13.4, 18.8) 3.72 (2.74, 5.05) 
TPA>median & CRP <1 mg/L 1298 69 8.0 (6.3, 10.1) 1.85 (1.28, 2.68)  1262 108 13.0 (10.7, 15.7) 2.67 (1.97, 3.62) 
TPA>median & CRP 1-3 mg/L 1832 111 9.2 (7.7, 11.1) 2.04 (1.45, 2.86)  1805 219 18.8 (16.5, 21.5) 3.71 (2.83, 4.88) 
TPA>median & CRP >3 mg/L 1232 137 18.2 (15.4, 21.5) 4.07 (2.93, 5.66)  1219 161 21.2 (18.2, 24.8) 4.17 (3.14, 5.54) 
Men      
No plaque & CRP <1 mg/L 1441 26 2.8 (1.9, 4.0) Ref.  1422 37 4.0 (1.7,  3.2) Ref. 
No plaque & CRP 1-3mg/L 1444 34 3.7(2.6, 5.1) 1.10 (0.66, 1.84)  1424 87 9.6 (7.8, 11.9) 2.20 (1.49, 3.23) 
No plaque & CRP >3 mg/L 658 29 7.0 (4.9, 10.1) 2.08 (1.22, 3.53)  647 54 13.5 (10.3, 17.6) 3.01 (1.98, 4.57) 
TPA<median & CRP <1 mg/L 778 24 4.8 (3.2, 7.1) 1.19 (0.68, 2.08)  760 53 10.9 (8.3, 14.2) 2.20 (1.44, 3.36) 
TPA<median & CRP 1-3 mg/L 873 41 7.3 (5.4, 9.9) 1.64 (1.00, 2.69)  854 65 11.8 (9.3, 15.1) 2.27 (1.51, 3.42) 
TPA<median & CRP >3 mg/L 463 28 9.8 (6.8, 14.2) 2.14 (1.25, 3.66)  450 55 20.3 (15.6, 26.4 3.85 (2.53, 5.87) 
TPA>median & CRP <1 mg/L 601 33 8.6 (6.1, 12.2) 1.62 (0.96, 2.73)  576 59 16.3 (12.6, 21.0) 2.82 (1.86, 4.28) 
TPA>median & CRP 1-3 mg/L 892 55 9.7 (7.4, 12.6) 1.78 (1.11, 2.86)  878 130 23.6 19.9, 28.1) 4.06 (2.80, 5.90) 
TPA>median & CRP >3 mg/L 622 75 20.9 (16.7, 26.2) 3.81 (2.42, 6.01)  611 93 25.9 (21.2, 31.8) 4.39 (2.98, 6.48) 
Women      
No plaque & CRP <1 mg/L 2343 25 1.7 (1.1, 2.4) Ref.  2340 35 2.3 (1.7, 3.2) Ref. 
No plaque & CRP 1-3mg/L 1992 37 2.8 (2.1, 3.9) 1.42 (0.86, 2.37)  1985 53 4.1 (3.1, 5.3) 1.44 (0.94, 2.21) 
No plaque & CRP >3 mg/L 1067 26 3.7 (2.5, 5.5) 1.81 (1.04, 3.14)  1063 34 4.9 (3.5, 6.9) 1.66 (1.04, 2.67) 
TPA<median & CRP <1 mg/L 830 17 3.1 (1.9, 5.0) 1.21 (0.65, 2.25)  821 29 5.5 (3.9, 7.9) 1.59 (0.98, 2.60) 
TPA<median & CRP 1-3 mg/L 883 38 6.3 (4.6, 8.7) 2.06 (1.24, 3.51)  870 43 7.2 (5.4, 9.7) 1.85 (1.18, 2.89) 
TPA<median & CRP >3 mg/L 534 29 8.2 (5.7, 11.8) 2.92 (1.70, 5.01)  530 46 13.2 (9.9, 17.7) 3.41 (2.19, 5.31) 
TPA>median & CRP <1 mg/L 697 36 7.5 (5.4, 10.3) 2.09 (1.24, 3.51)  686 49 10.4 (7.9, 13.8) 2.41 (1.55, 3.74) 
TPA>median & CRP 1-3 mg/L 940 56 8.9 (6.8, 11.5) 2.31 (1.43, 3.76)  927 89 14.5 (11.8, 17.9) 3.17 (2.13, 4.73) 












† Crude incidence rates per 1000 person-years.  









Table S7. Additive interaction of C-reactive protein (CRP) and categories of total plaque area (TPA) on risk of first-ever 
ischemic stroke and myocardial infarction. The Tromsø Study. 
 Ischemic stroke Myocardial infarction 
Exposure HR* (95% CI) HR* (95% CI) 
CRP >3 mg/L & no plaque 1.93 (1.32, 2.82) 2.36 (1.73, 3.22) 
TPA >median & CRP <1 mg/L 1.85 (1.28, 2.68) 2.67 (1.97, 3.62) 
CRP >3 mg/L & TPA>median 4.07 (2.93, 5.66) 4.17 (3.14, 5.54) 
         
Measure Estimate (95% CI) Estimate (95% CI) 
Relative excess risk due to interaction (RERI) 1.29 (0.32,  2.25) 0.13 (-0.82,  1.08) 
Attributable proportion (AP) 0.32 (0.10,  0.53) 0.03 (-0.20, 0.26) 
Synergy index  1.72 (1.06, 2.81) 1.04 (0.77, 1.42) 

















Table S8. Hazard ratios (HRs) with 95% confidence intervals (CIs) per standard deviation increase in 
C-reactive protein (CRP)* across categories of total plaque area (TPA). Assessment of multiplicative 
interaction. The Tromsø Study. 
 
 Ischemic stroke  Myocardial infarction 
 HR†  
(95% CI)  
HR‡  
(95% CI) 
 HR†  




































      
Interaction 
 p-value 
0.65 0.66  0.44 0.45 
*Log-transformed. 
† Adjusted for age and sex. 
‡ Adjusted for age, sex, smoking, systolic blood pressure, total cholesterol, high-density lipoprotein 
cholesterol, diabetes mellitus, body mass index, lipid lowering medication and antihypertensive 









Table S9. Crude incidence rates (IRs) and hazard ratios (HRs) with 95% confidence intervals (CIs) of first-ever ischemic stroke from time-fixed* Cox models across risk categories 









Model 1‡  
HR (95% CI) 
Model 2§  
HR (95% CI) 
Both sexes||   
< 1 mg /L 4158 211 4.2 (3.7–4.8) Reference Reference 
1–3 mg/L 3898 258 5.9 (5.3–6.7) 1.25 (1.05–1.50) 1.14 (0.95–1.37) 
> 3 mg/L 2053 202 9.6 (8.4–11.1) 2.05 (1.69–2.50) 1.71 (1.40–2.09) 
Men 
< 1 mg /L 1738 103 4.9 (4.0–5.9) Reference Reference 
1–3 mg/L 1769 138 7.1 (6.0–8.4) 1.32 (1.03–1.71) 1.21(0.93–1.57) 
> 3 mg/L 898 104 11.5 (9.5–14.0) 2.12 (1.61–2.78) 1.76 (1.33–2.35) 
Women 
< 1 mg /L 2420 108 3.7 (3.1–4.5) Reference Reference 
1–3 mg/L 2129 120 5.0 (4.2–6.0) 1.18 (0.90–1.54) 1.08 (0.82–1.41) 
> 3 mg/L 1155 98 8.2 (6.7–10.0) 2.00 (1.52–2.63) 1.67 1.25–2.23) 
*Values of exposure variables at time of study entrance.**Participants. †Crude IRs per 1000 person-years. ‡ Adjusted for age (|| and sex). §Adjusted for age, smoking, total 









Table 10. Crude incidence rates (IRs) and hazard ratios (HRs) with 95% confidence intervals (CIs) of first-ever myocardial infarction from time-fixed* Cox models across risk 









Model 1‡  
HR (95% CI) 
Model 2§  
HR (95% CI) 
Both sexes|| 
< 1 mg /L 4158 339 6.8 (6.2–7.6) Reference Reference 
1–3 mg/L 3898 452 10.6 (9.7–11.7) 1.38 (1.20–1.59) 1.16 (1.00–1.34) 
> 3 mg/L 2053 288 13.9 (12.4–15.6) 1.78 (1.53–2.09) 1.32 (1.12–1.56) 
Men 
< 1 mg /L 1738 194 9.4 (8.2–10.8) Reference Reference 
1–3 mg/L 1769 272 14.6 (12.9–16.4) 1.41 (1.18–1.70) 1.22 (1.01–1.47) 
> 3 mg/L 898 167 18.9 (16.2–22.0) 1.80 (1.46–2.21) 1.37 (1.11–1.70) 
Women 
< 1 mg /L 2420 145 5.0 (4.3–5.9) Reference Reference 
1–3 mg/L 2129 180 7.6 (6.5–8.8) 1.33 (1.07–1.65) 1.08 (0.86–1.36) 
> 3 mg/L 1155 121 10.2 (8.5–12.2) 1.79 (1.40–2.28) 1.28 (0.99–1.66) 
*Values of exposure variables at time of study entrance.**Participants. †Crude IRs per 1000 person-years. ‡ Adjusted for age (|| and sex). §Adjusted for age, smoking, total 








Table S11. Crude incidence rates (IRs) and hazard ratios (HRs) with 95% confidence intervals (CIs) of first-ever ischemic stroke from time-fixed* Cox models across categories of 
total plaque area (TPA), before and after adjustment for C-reactive protein (CRP). The Tromsø Study. 
 
TPA n **  Events IR† (95% CI) 
Model 1‡  
HR (95% CI) 
Model 1‡ + CRP  
HR (95% CI) 
Absolute attenuation of HR 
after inclusion of CRP in the 
model§ 
Percentage attenuation of HR 
after inclusion of CRP in the 
model 
Model 2|| HR  
(95% CI) 
Both sexes# 
No plaque 5711 233 3.5 (3.1–4.0) Reference Reference – – Reference 
TPA<median 2198 175 6.7 (5.8–7.8) 1.33 (1.09–1.62) 1.33 (1.09–1.62) 0 – 1.28 (1.05–1.56) 
TPA>median 2200 263 11.5 (10.2–13.0) 2.00 (1.67–2.42) 1.92 (1.60–2.31) 0.08  8.0 1.69 (1.39–2.04) 
Men 
No plaque 2284 114 4.3 (3.6–5.2) Reference Reference – – Reference 
TPA<median 1060 96 6.9 (6.2–9.3) 1.27 (0.97–1.68) 1.27 ( 0.96–1.67) 0.00 – 1.20 (0.91–1.59) 
TPA>median 1061 135 12.8 (10.8-15.1) 1.91 (1.47–2.48) 1.79 (1.38–2.32) 0.12 13.2 1.57 (1.20–2.05) 
Women 
No plaque 3427 119 3.0 (2.5–3.6) Reference Reference – – Reference 
TPA<median 1139 79 5.9 (4.7–7.3) 1.39 (1.04–1.85) 1.39 (1.05–1.86) 0.00  – 1.37 (1.03–1.83) 
TPA>median 1138 128 10.4 (8.8–12.4) 2.10 (1.62–2.73) 2.05 (1.57–2.66) 0.05 4.5 1.83 (1.40–2.40) 
*Values of exposure variables at time of study entrance.**Participants. †Crude IRs per 1000 person-years. ‡Adjusted for age (# and sex). §Absolute attenuation of HR after inclusion of 
CRP in the model (i.e. change in HR from Model 1 to Model 1 + CRP). CRP was log-transformed. || Adjusted for age, CRP (log-transformed), smoking, total cholesterol, high-density 









Table S12. Crude incidence rates (IRs) and hazard ratios (HRs) with 95% confidence intervals (CIs) of first-ever myocardial infarction from time-fixed* Cox models across 
categories of total plaque area (TPA), before and after adjustment for C-reactive protein (CRP). The Tromsø Study. 
 
TPA n **  Events IR† (95% CI) 
Model 1‡  
HR (95% CI) 
Model 1‡ + CRP  
HR (95% CI) 
Absolute attenuation of HR 
after inclusion of CRP in the 
model§ 
Percentage attenuation of HR 
after inclusion of CRP in the 
model 
Model 2|| HR  
(95% CI) 
Both sexes# 
No plaque 5711 385 5.9 (5.4–6.6) Reference Reference – – Reference 
TPA<median 2200 394 11.8 (10.5–13.2) 1.45 (1.24–1.69) 1.44 (1.24–1.68) 0.01  2.2 1.31 (1.12–1.52) 
TPA>median 2198 300 17.6 (16.5–19.5) 1.97 (1.70–2.29) 1.90 (1.64–2.20) 0.07 7.2 1.49 (1.28–1.73) 
Men 
No plaque 2284 229 9.0 (7.9–10.2) Reference Reference – – Reference 
TPA<median 1061 172 14.0 (12.1–16.3) 1.24 (1.01–1.51) 1.23 (1.00–1.50) 0.01  4.2 1.12(0.92–1.37) 
TPA>median 1060 232 22.6 (19.8-25.6) 1.80 (1.49–2.18) 1.72 (1.41–2.08) 0.08 10.0 1.43 (1.17–1.74) 
Women 
No plaque 3427 156 4.0 (3.4–4.7) Reference Reference – – Reference 
TPA<median 1139 128 14.0 (12.1–16.3) 1.81(1.43–2.30) 1.81 (1.43–2.30) 0.00  – 1.64 (1.29–2.08) 
TPA>median 1138 162 12.6 (19.8–25.6) 2.22 (1.76–2.79) 2.17 (1.72–2.73) 0.05  4.1 1.63 (1.29–2.06) 
*Values of exposure variables at time of study entrance.**Participants. †Crude IRs per 1000 person-years. ‡Adjusted for age (# and sex). §Absolute attenuation of HR after inclusion of 
CRP in the model (i.e. change in HR from Model 1 to Model 1 + CRP). CRP was log-transformed. || Adjusted for age, CRP (log-transformed), smoking, total cholesterol, high-density 













Table S13. Incidence rates (IRs) and hazard ratios (HRs) with 95% confidence intervals (CIs) of first-ever ischemic stroke (IS) and myocardial infarction (MI) from 
time-fixed* Cox models across constellations of C-reactive protein (CRP) and categories of total plaque area (TPA). The Tromsø Study. 
 
 Ischemic stroke                                Myocardial infraction 












Both sexes ||      
No plaque & CRP <1 mg/L 2565 88 2.8 (2.3, 3.5) Ref.  2565 134 4.4 (3.7, 5.2) Ref. 
No plaque & CRP 1-3mg/L 2149 84 3.5 (2.8, 4.3) 1.07 (0.79, 1.44)  2149 159 6.7 (5.8, 7.9) 1.36 (1.08, 1.71) 
No plaque & CRP >3 mg/L 997 61 5.8 (4.5, 7.4) 1.90 (1.37, 2.64)  997 92 8.8  (7.2, 10.8) 1.89 (1.45, 2.47) 
TPA<median & CRP <1 mg/L 912 55 4.7 (3.6, 6.2) 1.11 (0.79, 1.56)  912 106 9.4 (7.8, 11.3) 1.52 (1.17, 1.96) 
TPA<median & CRP 1-3 mg/L 825 73 7.7 (6.1, 9.6) 1.78 (1.30, 2.44)  825 117 12.4 (10.4, 14.9) 1.96 (1.53, 2.52) 
TPA<median & CRP >3 mg/L 461 47 9.6 (7.2, 12.8) 2.20 (1.54, 3.15)  461 77 16.1 (12.9, 20.1) 2.52 (1.89, 3.34) 
TPA>median & CRP <1 mg/L 681 68 9.1 (6.3, 10.1) 1.87 (1.35, 2.58)  681 99 13.5 (11.1, 16.4) 2.00 (1.54, 2.61) 
TPA>median & CRP 1-3 mg/L 924 101 10.3 (8.4, 12.5) 2.10 (1.57, 2.82)  924 176 18.6 (16.0, 21.5) 2.69 (2.14, 3.39) 
TPA>median & CRP >3 mg/L 594 94 17.2 (14.0, 21.0) 3.58 (2.66, 4.83)  595 119 21.6 (18.0, 25.8) 3.06 (2.37, 3.94) 
Men      
No plaque & CRP <1 mg/L 990 41 3.4 (2.5, 4.6) Ref.  990 77 6.4 (5.2,  8.1) Ref. 
No plaque & CRP 1-3mg/L 912 44 4.4 (3.3, 5.9) 1.12(0.73, 1.72)  912 97 10.0 (8.2, 12.2) 1.29 (1.01, 1.88) 
No plaque & CRP >3 mg/L 382 29 7.1 (4.9, 10.2) 1.96 (1.22, 3.17)  383 55 14.1 (10.8, 18.4) 2.05 (1.45, 2.90) 
TPA<median & CRP <1 mg/L 437 28 4.8 (3.3, 5.9) 0.98 (0.60, 1.59)  437 60 10.8 (8.4, 13.9) 1.28 (0.91, 1.80) 
TPA<median & CRP 1-3 mg/L 408 44 9.6 (7.2, 12.9) 1.95 (1.27, 3.00)  408 72 16.0 (12.7, 20.2) 1.85 (1.34, 2.56) 
TPA<median & CRP >3 mg/L 215 24 10.6 (7.1, 15.8) 2.11 (1.27, 3.51)  215 40 18.1 (13.3, 24.7) 2.09 (1.42, 3.07) 
TPA>median & CRP <1 mg/L 311 34 10.7 (7.6, 15.0) 1.92 (1.21, 3.51)  311 57 18.3 (14.1, 23.8) 1.95 (1.38, 2.77) 
TPA>median & CRP 1-3 mg/L 449 50 10.6 (8.1, 14.0) 1.94 (1.28, 2.96)  449 103 23.2 19.1, 28.1) 2.49 (1.84, 3.38) 
TPA>median & CRP >3 mg/L 301 51 19.0 (14.4, 25.0) 3.43 (2.24, 5.23)  301 72 26.3 (20.9, 33.1) 2.76 (1.98, 3.84) 
Women      
No plaque & CRP <1 mg/L 1575 47 2.5 (1.8, 3.3) Ref.  1575 57 3.0 (2.4, 3.6) Ref. 
No plaque & CRP 1-3mg/L 1237 40 2.9 (2.1, 3.9) 1.02 (0.67, 1.55)  1237 62 4.5 (3.5, 5.7) 1.31 (0.91, 1.87) 
No plaque & CRP >3 mg/L 615 32 4.9 (3.5, 6.9) 1.86 (1.19, 2.92)  615 37 5.7 (4.1, 7.8) 1.72 (1.14, 2.60) 
TPA<median & CRP <1 mg/L 475 27 4.6 (3.2, 6.7) 1.30 (0.81, 2.09)  475 46 8.0 (6.0, 10.7) 1.94 (1.31, 2.86) 
TPA<median & CRP 1-3 mg/L 417 29 5.8 (4.1, 8.4) 1.57 (0.98, 2.50)  417 45 9.2 (6.9, 12.3) 2.11 (1.42, 3.12) 
TPA<median & CRP >3 mg/L 246 23 8.8 (5.8, 13-1) 2.30 (1.39, 3.81)  245 37 14.3 (10.4, 19.8) 3.17 (2.09, 4.82) 
TPA>median & CRP <1 mg/L 370 34 7.8 (5.6, 11.0) 1.81 (1.16, 2.84)  370 42 9.9 (7.3, 13.4) 2.05 (1.37, 3.07) 
TPA>median & CRP 1-3 mg/L 475 51 9.9 (7.5, 13.1) 2.27 (1.52, 3.41)  475 73 14.5 (11.5, 18.2) 2.94 (2.06, 4.19) 

















 Table S14. Performance of time-fixed* Cox regression models for ischemic stroke (IS) with addition of total plaque area (TPA), C-reactive protein (CRP) and both (TPA+CRP) compared to 
Framingham risk factor based model. The Tromsø Study. 
Performance measure Framingham risk 
factor model 
+TPA† +CRP† +Both† +TPA‡ +CRP‡ +Both‡ 















(0.7342,  0.7714) 
p-value  0.040 0.394 0.010 0.045 0.104 0.002 
NRI 
Estimated incident IS at 10 years follow-up (n=490) § 
% cases moved up||  12.3 10.8 19.3 11.7 13.5 17.8 
% cases moved down||  10.0 8.1 12.6 9.5 5.4 13.2 
NRI for IS cases, % (95% CI)  2.3 (-2.5, 7.1) 2.8 (-1.9, 7.) 6.6 (1.9, 11.3) 2.2  (-1.7, 6.1) 3.8 (-0.5, 8.0) 4.6 (0.3, 8.9) 
p-value  0.226 0.214 0.005 0.280 0.069 0.036 
Estimated non-events (controls) at 10 years follow-up (n=9619) § 
% non-events moved up||  5.6 4.5 7.1 6.5 5.7 7.7 
% non-events moved down||  6.4 3.9 7.1 6.3 5.4 7.6 
NRI for controls, % (95% CI)  0.6 (-0.8, 2.0) -0.5 (1.9, 1.4) -0.03 (-1.5, 1.2) -0.2 (-0.1, 1.6) -0.03 (-1.8 , 1.2) -0.1 (-1.5, 1.3) 
p-value  0.369 0.400 0.956 0.773 0.675 0.849 
Overall categorical NRI||, % (95% CI)  2.8  (-2.0, 7.6) 2.2  (-2.7, 6.9) 6.6 (1.8, 11.4) 2.1 (-2.1, 6.3) 3.6 (-0.8, 8.0) 4.5 (-0.1, 9.1) 
p-value  0.226 0.338 0.007 0.35 0.110 0.051 
        
Continuous NRI, % (95% CI)  19.8  (5.5, 34.1) 20.1 (5.0, 35.2) 22.2 (8.7, 35.7) 22.8 (11.2, 34.4) 19.5 (8.6, 31.3) 31.1 (16.6, 45.8) 
p-value  0.002 0.002 <0.001 <0.001 <0.001 <0.001 
        
Relative IDI, % (95% CI)  0.16 (0.03, 0.29) 0.09 (-0.03, 0.21) 0.24 (0.09, 0.38) 0.09 (0.02, 0.17) 0.13 (0.06, 0.20) 0.22 (0.09, 0.35) 
p-value  0.0023 0.075 <0.001 0.03 <0.001 <0.001 
        
HL-X2 9.96 10.33 10.63 8.67 8.25 8.21 11.8 
p-value 0.268 0.240 0.220 0.498 0.410 0.413 0.159 
NRI, net reclassification improvement; IDI, integrated discrimination improvement; HL-X2, Hosmer-Lemeshow chi2 test; CI, confidence interval. Framingham risk factor model includes sex, age, 
systolic blood pressure, high-density lipoprotein cholesterol, total cholesterol, smoking and antihypertensive medication. *Values of exposure variables at time of study entrance. † Included as 
continuous variables TPA (square root transformed), CRP (log transformed). ‡  Included as categorical variables; TPA (no plaque, < median and > median, with no plaque as reference category); 
CRP (<1 mg/L, 1-3 mg/L and >3 mg /L, with CRP <1 mg/L as reference category). § All observed risks have been interpolated to 10-year event rates by Kaplan Meier risk estimates using the 









Table S15. Performance of time-fixed* Cox regression models for myocardial infarction (MI) with addition total plaque area (TPA), C-reactive protein (CRP) and both (TPA+CRP) compared to 
Framingham risk factor-based model. The Tromsø Study. 
 
Performance measure Framingham risk 
factor model 

















p-value  0.013 0.535 <0.001 0.016 0.386 0.003 
NRI 
Estimated incident MI at 10 years follow-up (n=895) § 
% cases moved up||  11.4 8.0 11.9 12.1 9.2 13.4 
% cases moved down||  8.8 4.3 9.3 8.9 5.5 9.1 
NRI for MI cases, % (95% CI)  2.5 (-0.5, 5.5) 3.7 (0.3-7.1) 2.6 (- 1.0, 6.2) 3.2 (-0.01, 6.6) 3.7 (0.1, 7.3) 4.3 (0.5, 8.0) 
p-value  0.052 0.038 0.16 0.06 0.049 0.025 
Estimated non-events (controls) at 10 years follow-up (n=9214) § 
% non-events moved up||  6.2 3.3 6.6 7.0 4.6 7.8 
% non-events moved down||  7.4 3.3 7.6 8.0 4.6 8.5 
NRI for controls, % (95% CI)  1.2 (0.2, 2.2) 0.02 (-1.3, 1.7) 1.0 (-0.3, 2.3) 1.0 (0.2, 1.8) -0.02 (-0.5 , 0.5) 0.7 (-0.6, 1.7) 
p-value  0.049 0.973 0.10 0.015 0.974 0.240 
Overall categorical NRI||, % (95% CI)  3.8 (0.6, 7.0) 3.7 (-0.1, 7.5) 3.6 (-0.01, 7.3) 4.2 (0.5, 7.3) 3.7 (-0.01, 7.1) 5.0 (1.2, 8.7) 
p-value  0.03 0.051 0.062 0.029 0.055 0.011 
 
Continuous NRI, % (95% CI)  19.4 (12.6, 27.0) 22.0 (13.6, 30.4) 13.8 (3.3, 24.3) 26.7 (19.5, 33.9) 13.0 (-0.02, 28.2) 20.6 (9.7, 31.5) 
p-value  <0.001 <0.001 0.007 <0.001 0.098 <0.001 
        
Relative IDI, % (95% CI)  0.07 (0.05, 0.10) 0.03 (-0.01, 0.07) 0.09 (0.04, 0.15) 0.04 (0.02, 0.06) 0.04 (0.02, 0.05) 0.07 (0.02, 0.11) 
p-value  <0.001 0.174 0.002 0.030 0.041 0.012 
        
HL-X2 40.7 29.4 44.6 29.0 29.9 40.65 29.6 
p-value <0.0001 <0.0001 <0.0001 0.0003 <0.0001 <0.0001 <0.0001 
NRI, net reclassification improvement; IDI, integrated discrimination improvement; HL-X2, Hosmer-Lemeshow chi2 test; CI, confidence interval. Framingham risk factor model includes sex, age, 
systolic blood pressure, high-density lipoprotein cholesterol, total cholesterol, smoking and antihypertensive medication.*Values of variables at time of study entrance. † Included as 
continuous variables TPA (square root transformed), CRP (log transformed). ‡  Included as categorical variables; TPA (no plaque, < median and > median, with no plaque as reference category); 
CRP (<1 mg/L, 1-3 mg/L and >3 mg /L, with CRP <1 mg/L as reference category). § All observed risks have been interpolated to 10-year event rates by Kaplan Meier risk estimates using the 









Table S16. Performance of time-fixed* Cox regression models for ischemic stroke (IS) in subjects at intermediate risk (5-20%, n=2994) with addition of total plaque area (TPA), C-reactive protein 
(CRP) and both (TPA+CRP) compared to Framingham risk factor-based model. The Tromsø Study. 
 
Performance measure  +TPA† +CRP† +Both† +TPA‡ +CRP‡ +Both‡ 
NRI 
Estimated incident IS at 10 years follow-up (n=299) § 
% cases moved up||  14.7 13.3 24.4 15.2 16.6 22.1 
% cases moved down||  13.5 9.9 16.5 12.9 12.8 18.3 
NRI for IS cases, % (95% CI)  1.2 (-6.0, 8.4) 3.5 (-3.6, 10.6) 7.8 (-0.4, 16.0) 2.2  (-4.5, 8.9) 3.8 (-3.3, 10.9) 3.8 (-3.3, 10.9) 
p-value  0.74 0.33 0.06 0.52 0.29 0.29 
Estimated non-events (controls) at 10 years follow-up (n=2695) § 
% non-events moved up||  8.8 6.4 10.4 9.5 9.1 11.3 
% non-events moved down||  21.9 13.1 24.2 21.6 17.9 25.8 
NRI for controls, % (95% CI)  13.3 (9.0, 17.6) 6.7 (1.0, 12.4) 13.8 (8.1, 19.5) 12.1 (9.9, 14.3) 8.8 (5.1, 12.5) 14.5 (10.2, 18.8) 
p-value  <0.001 0.02 <0.001 <0.001 <0.001 <0.001 
Overall categorical NRI||, % (95% CI)  14.4  (6.6, 22.2) 10.1  (2.3, 17.9) 21.6 (11.0, 32.2) 14.3 (7.1, 21.4) 12.6 (5.2, 20.1) 18.3 (10.3, 26.3) 
p-value  <0.001 0.016 <0.001 <0.001 0.001 <0.001 
        
Continuous NRI, % (95% CI)  21.0 (6.7, 35.3) 24.7 (10.4 ,39.0 ) 30.8 (15.3, 46.3) 24.8 (11.1, 38.5) 20.8 (6.9, 34.7) 30.5 (16.0, 45.0) 
p-value  0.004 <0.001 <0.001 <0.001 0.004 <0.001 
        
Relative IDI, % (95% CI)  0.46 (0.23, 0.69) 0.32 (0.09, 0.56) 0.78 (0.43, 1.13) 0.38 (0.33, 0.43) 0.48 (0.36, 0.60) 0.86 (0.59, 1.13) 
p-value  <0.001 0.007 <0.001 0.01 <0.001 <0.001 
NRI, net reclassification improvement; IDI, integrated discrimination improvement; CI, confidence interval. Framingham risk factor model includes sex, age, systolic blood pressure, high-
density lipoprotein cholesterol, total cholesterol, smoking and antihypertensive medication. *Values of variables at time of study entrance. † Included as continuous variables, TPA (square root 
transformed), CRP (log transformed). ‡  Included as categorical variables; TPA (no plaque, < median and > median, with no plaque as reference category); CRP (<1 mg/L, 1-3 mg/L and >3 mg /L, 
with CRP <1 mg/L as reference category). § All observed risks have been interpolated to 10-year event rates by Kaplan Meier risk estimates using the actual observed events over a median 









Table S17. Performance of time-fixed* Cox regression models for myocardial infarction (MI) in subjects at intermediate risk (5-20%, n=5250) with addition of total plaque area (TPA), C-reactive 
protein (CRP) and both (TPA+CRP) compared to Framingham risk factor-based model. The Tromsø Study. 
 
Performance measure  +TPA† +CRP† +Both† +TPA‡ +CRP‡ +Both‡ 
NRI 
Estimated incident MI at 10 years follow-up (n=562) § 
% cases moved up||  15.4 10.3 15.0 16.4 11.5 17.3 
% cases moved down||  9.6 4.6 10.5 10.5 6.7 10.6 
NRI for MI cases, % (95% CI)  5.7 (-1.6, 13.0) 5.7 (-1.4, 12.8) 4.5 (-2.4, 11.4) 5.9 (-1.9, 13.7) 4.8 (-2.6, 12.2) 6.7 (-0.7, 14.1) 
p-value  0.12 0.11 0.20 0.14 0.21 0.08 
Estimated non-events (controls)  at 10 years follow-up (n=4688) § 
% non-events moved up||  7.7 3.4 8.0 8.3 4.8 9.4 
% non-events moved down||  12.5 5.9 12.9 13.9 8.1 14.6 
NRI for controls, % (95% CI)  4.8 (-2.8, 12.4) 2.5 (-5.5, 10.5) 4.8 (-3.0, 11.8) 5.6 (-0.8, 12.0) 3.3(-4.3, 10.9) 5.3 (2.3, 12.9) 
p-value  0.22 0.55 0.23 0.06 0.40 0.18 
Overall categorical NRI||, % (95% CI)  10.5 (1.3, 19.7) 8.2 (-1.6, 18.0) 9.3 (-0.3, 18.9) 11.6 (1.4, 21.8) 8.1  (-2.3, 18.5) 12.0 (2.0, 22.0) 
p-value  0.04 0.10 0.06 0.03 0.13 0.02 
 
Continuous NRI, % (95% CI)  18.2 (0.4, 20.3) 18.2 (1.0, 35.4) 14.9 (-2.2, 32.0) 15.1 (-1.2, 31.4) 7.1 (-11.9, 26.1) 17.0 (-1.4, 35.4) 
p-value  0.05 0.04 0.09 0.07 0.463 0.07 
        
Relative IDI, % (95% CI)  0.24 (-0.15, 0.64) 0.06 (-0.35, 0.47) 0.28 (-0.11, 0.67) 0.22 (-0.15, 0.59) 0.09 (-0.34, 0.52) 0.30 (-0.11, 0.71) 
p-value  0.24 0.78 0.18 0.25 0.67 0.14 
NRI, net reclassification improvement; IDI, integrated discrimination improvement; CI, confidence interval. Framingham risk factor model includes sex, age, systolic blood pressure, high-
density lipoprotein cholesterol, total cholesterol, smoking and antihypertensive medication. *Values of variables at time of study entrance. † Included as continuous variables, TPA (square root 
transformed), CRP (log transformed). ‡  Included as categorical variables; TPA (no plaque, < median and > median, with no plaque as reference category); CRP (<1 mg/L, 1-3 mg/L and >3 mg /L, 
with CRP <1 mg/L as reference category). § All observed risks have been interpolated to 10-year event rates by Kaplan Meier risk estimates using the actual observed events over a median 
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